American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
The pharmacology, pharmacokinetics, efficacy, and safety of the tyrosine kinase inhibitor (TKI) bosutinib in the management of chronic myeloid leukemia (CML) are reviewed. ⋯ Bosutinib is a safe and effective second-line treatment option for select patients with Ph-positive CML who were intolerant or resistant to prior TKI therapy.
-
Am J Health Syst Pharm · Feb 2015
Observational StudyImpact of a clinical pharmacy research team on pharmacy resident research.
A successful initiative by Kaiser Permanente Colorado (KPCO) to support pharmacy resident research projects and the publication of project results in peer-reviewed journals is described. ⋯ An increase in the proportion of pharmacy resident research projects published in peer-reviewed journals was observed after the CPRT was established.
-
Am J Health Syst Pharm · Feb 2015
Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
A cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia (CD) was conducted. ⋯ A cost-utility analysis found that Xeomin was the more cost-effective botulinum toxin type A product compared with Botox and Dysport for the treatment of CD. Wastage associated with the respective products may have a large effect on the cost-effectiveness of the agents.
-
Am J Health Syst Pharm · Feb 2015
Case ReportsUse of low-dose prothrombin complex concentrate before lumbar puncture.
The use of an off-label dose of four-factor prothrombin complex concentrate (PCC) for International Normalized Ratio (INR) reversal in a patient before a diagnostic lumbar puncture is reported. ⋯ A 57-year-old patient was successfully treated with low-dose PCC to reverse an INR from 1.7 to 1.3 in order to perform a diagnostic lumbar puncture.